Faron Pharmaceuticals LTD: Holding(S) In Company

TURKU, FI / ACCESS Newswire / June 17, 2026 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN)

Faron Pharmaceuticals Ltd | Company announcement | June 17, 2026 at 09:00:00 EEST

Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FIN-FSA)
1. Identity of the issuer: FARON PHARMACEUTICALS OY
2. Reason for the notification (please tick the appropriate box or boxes): ? An acquisition or disposal of shares or voting rights ? An acquisition or disposal of financial instruments ? An event changing the breakdown of shares or voting rights ? Other (please specify): Click here to enter text.
3. Details of person subject to the notification obligation:
Name: Bank of America Corporation		City and country of residence: Wilmington, DE, United States of America
4. Full name of shareholder(s) (if different from 3.): -
5. Date on which the threshold was crossed or reached: 12.6.2026
6. Total positions of person(s) subject to the notification obligation:
	% of shares and voting rights (total of 7.A)		% of shares and voting rights through financial instruments (total of 7.B)	Total of both in % (7.A + 7.B)	Total number of shares and voting rights of issuer
Resulting situation on the date on which threshold was crossed or reached	0.12		9.99	10.11	206,411,888
Position of previous notification (if applicable)	0.13		10.07	10.20

7. Notified details of the resulting situation on the date on which the threshold was crossed or reached:
A: Shares and voting rights
Class/type of shares ISIN code (if possible)		Number of shares and voting rights				% of shares and voting rights
		Direct (SMA 9:5)		Indirect (SMA 9:6 and 9:7)		Direct (SMA 9:5)		Indirect (SMA 9:6 and 9:7)
FI4000153309		0		246,335		0		0.12
-		-		-		-		-
-		-		-		-		-
SUBTOTAL A		246,335				0.12
B: Financial Instruments according to SMA 9:6a
Type of financial instrument	Expiration date		Exercise/ Conversion Period		Physical or cash settlement		Number of shares and voting rights		% of shares and voting rights
Rights of Use	n/a		n/a		n/a		20,374,993		9.87
Swaps		15/10/2027		n/a	Cash		245,294		0.12
-	-		-		-		-		-
					SUBTOTAL B		20,620,287		9.99

8. Information in relation to the person subject to the notification obligation (please tick the applicable box): ? Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer. ? Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity:
Name	% of shares and voting rights	% of shares and voting rights through financial instruments	Total of both
-	-	-	-
-	-	-	-
-	-	-	-
-	-	-	-
-	-	-	-
9. In case of proxy voting: [name of the proxy holder] will cease to hold [% and number] voting rights as of Click here to enter a date.
10. Additional information:

Done at London, United Kingdom on 15.6.2026.

SOURCE: Faron Pharmaceuticals

View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/biotechnology/faron-pharmaceuticals-ltd-holdings-in-company-1178486